Maya M. Zeineddine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Maya M. Zeineddine has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Bassem Yamout
Neurology Institute, Harley Street Medical Center, Abu Dhabi, United Arab Emirates
3 shared publications - Samia Joseph Khoury
Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Beirut, Lebanon
3 shared publications Bassem I. Yamout
Nehme and Therese Tohme Multiple Sclerosis Center, Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon
2 shared publicationsHani Tamim
Clinical Research Institute, American University of Beirut Medical Center, Beirut, Lebanon
2 shared publicationsBassem I Yamout
Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Lebanon
1 shared publicationG. Saab
Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon
1 shared publication
Latest Publications
- 1 May 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 40, 101947
Neurobrucellosis presenting as longitudinally extensive transverse myelitis: A case report and review of the literature
- 1 May 2020
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 40, 101947
Neurobrucellosis presenting as longitudinally extensive transverse myelitis: A case report and review of the literature
- Open Access
- 9 January 2020
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 6 (1)
Treatment of multiple sclerosis in special populations: The case of refugees
Multiple sclerosis was long considered a relatively rare entity in the Middle East, but research over the past 10 years and the publication of the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis guidelines for multiple sclerosis have allowed diagnosis and treatment to occur more efficiently. Most of the first and second-line disease-modifying therapies approved by the Food and Drug Administration and the European Medicine Agency are available in the Middle East. However, the availability of disease-modifying therapies is quite variable, with some countries having access to all multiple sclerosis disease-modifying therapies, while in others there is only one therapeutic option. Economic limitations remain a challenge for the management of multiple sclerosis, especially in countries of war. Moreover, the burden of multiple sclerosis treatment in Syrian and Palestinian refugees is likely high due to the non-availability of funds to cover the high cost of disease-modifying therapies.
- 9 January 2020
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 6 (1)
Open AccessTreatment of multiple sclerosis in special populations: The case of refugees
Multiple sclerosis was long considered a relatively rare entity in the Middle East, but research over the past 10 years and the publication of the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis guidelines for multiple sclerosis have allowed diagnosis and treatment to occur more efficiently. Most of the first and second-line disease-modifying therapies approved by the Food and Drug Administration and the European Medicine Agency are available in the Middle East. However, the availability of disease-modifying therapies is quite variable, with some countries having access to all multiple sclerosis disease-modifying therapies, while in others there is only one therapeutic option. Economic limitations remain a challenge for the management of multiple sclerosis, especially in countries of war. Moreover, the burden of multiple sclerosis treatment in Syrian and Palestinian refugees is likely high due to the non-availability of funds to cover the high cost of disease-modifying therapies.
- 1 November 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 36, 101437
Skin warts during fingolimod treatment in patients with multiple sclerosis
- 1 November 2019
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 36, 101437
Skin warts during fingolimod treatment in patients with multiple sclerosis
- 1 August 2018
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 24, 113-116
Efficacy and safety of natalizumab extended interval dosing
- 1 August 2018
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 24, 113-116
Efficacy and safety of natalizumab extended interval dosing
- 1 December 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 289, 93-97
Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East
- 1 December 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 289, 93-97
Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East
- 1 August 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 285, 13-15
Safety and efficacy of reduced fingolimod dosage treatment
- 1 August 2015
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 285, 13-15
Safety and efficacy of reduced fingolimod dosage treatment